---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-078108"
form_type: "8-K"
ticker: "ATXI"
cik: "0001644963"
company_name: "AVENUE THERAPEUTICS, INC."
filed_at: "2023-07-05T23:59:59+00:00"
generated_at: "2026-06-13T12:42:11.934495+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Avenue Therapeutics grants options for 1.05M shares to CEO and Interim CFO

## Summary
- CEO Alexandra MacLean granted option to purchase 800,000 shares at $1.14/share.
- Interim CFO/COO David Jin granted option to purchase 250,000 shares at same price.
- Options vest in four equal annual installments beginning August 1, 2023.
- Options expire 10 years from grant dates (June 29, 2033 and June 30, 2033).

## SEC filing metadata
- accession: 0001104659-23-078108
- form_type: 8-K
- ticker: ATXI
- cik: 0001644963
- company_name: AVENUE THERAPEUTICS, INC.
- filed_at: 2023-07-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1644963/000110465923078108/0001104659-23-078108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1644963/000110465923078108/tm2320616d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-078108
- JSON: https://secwatch.observer/filing/0001104659-23-078108.json
- Plain text: https://secwatch.observer/filing/0001104659-23-078108.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.